Physician profile
John R Baker
NPI 1457388266
$2,109.09
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $575 · 2021: $667 · 2022: $47.83.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $424.92 | 2019-2021 | |
| Novo Nordisk INC | $297.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $225.22 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $215.04 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.64 | 2019-2021 | |
| Pfizer INC. | $159.32 | 2019-2021 | |
| Abbott Laboratories | $64.94 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.41 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $57.65 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $57.24 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.16 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $54.21 | 2021 | |
| Astellas Pharma US INC | $30.89 | 2020-2021 | |
| Amarin Pharma, INC. | $30.87 | 2021 | |
| Lilly USA, LLC | $29.15 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $24.17 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $23.08 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $20.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.03 | 2021 | |
| Dexcom, INC. | $16.29 | 2021 | |
| Shire North American Group INC | $16.25 | 2019 | |
| Genentech USA, INC. | $15.26 | 2020 | |
| Eisai INC. | $14.02 | 2020 | |
| Cardinal Health 200 LLC | $13.71 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.04 | 2019 | |
| Glaxosmithkline, LLC. | $11.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.